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Challenges of genetic counselling
In this issue of the Netherlands Heart Journal, two
manuscripts and an editorial emphasise the chal-
lenges of genetic counselling in cardiomyopathies.
Advances in genetic screening have increased the
number of genes that can be screened to trace dis-
ease-causing variants and enable the identification
of a large group of people at risk of developing car-
diac arrhythmias and heart failure. The downside, as
emphasised in this issue, is that the ability of screen-
ing a large panel of genes also uncovers many gene
variants of unknown clinical significance (VUS). After
the initial enthusiasm about expanded gene panels,
scientists became more and more aware that not
all known variants are pathogenic and are, in fact,
quite common in the general population. The use
of the term gene mutation is under debate as muta-
tion implies pathogenicity, while most newly detected
gene variants are not pathogenic. Thus, gene variant
would be a better term than mutation, and ‘gene
variant carrier’ may be used for persons who are at
risk of cardiomyopathy. Yet, at the same time, this is
where the clinical problem lies. The study by van Lint
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and colleagues shows that many gene variant carriers
may not be at risk of developing a cardiac arrhythmia
or cardiac disease [1]. The actual pathogenicity of
gene variants appears to vary from disease-causing to
being a disease modifier. From a clinical perspective,
a new discussion about the clinical utility of large
gene panels is warranted, and Dooijes, Siemelink and
Baas propose in their editorial that a national consen-
sus about smaller diagnostic gene panels with optimal
sensitivity and specificity would aid to optimise ge-
netic screening and counselling, and improve the
identification of persons with an actual pathogenic
gene variant [2].
Is there no use at all for large gene panels?
To define the exact role of relatively common genetic
variants in Mendelian disorders much more research
is required. Broad genetic screening and genome-
wide association studies (GWAS) do have relevance
for scientific studies to establish whether variants are
genetic modifiers, which may be either protective or
detrimental. GWAS analysis in a group of patients
with Brugada syndrome revealed a cumulative ef-
fect of three loci on disease susceptibility, indicating
an important modulating role for genetic polymor-
phisms in cardiac conduction disorders [3]. After the
first identification of variants in the gene encoding the
giant protein titin as cause of dilated cardiomyopa-
thy [4], follow-up studies indicated that these titin
gene variants are less pathogenic when compared
with, for instance, lamin variants [5]. Because of its
large size, many relatively common gene variants are
found in titin. While titin gene variants appear to be
less harmful compared with other dilated cardiomy-
opathy genes, studies in patients carrying titin gene
variants showed that increased cardiac stress during
an ‘acute’ event such as pregnancy initiates disease
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[6]. Moreover, other cardiac stress inducers such as
chemotherapy and alcohol predispose persons with
gene variants to development of disease [7, 8]. Even
proven disease-causing variants show a large clinical
heterogeneity in families, indicating that the actual
onset and progression of cardiomyopathy is the result
of the combined effect of gene variants and additional
genetic and environmental modifiers. Knowledge of
the role of genetic background (polymorphisms) in
addition to the pathogenic variant and environmental
factors is needed to fully understand the complex and
heterogeneous clinical phenotypes, which can range
from asymptomatic persons to persons with end-
stage heart failure in one family sharing the same
pathogenic variant.
What is needed to define factors that cause car-
diomyopathy?
International biobanks and registries with a large
number of gene variant carriers are needed to better
understand the initiation and progression of genetic
heart disease. An example of such an international
registry is SHaRe (Sarcomeric Human Cardiomyopa-
thy Registry), which recently reported the results of
patients followed in 8 experienced, high-volume hy-
pertrophic cardiomyopathy (HCM) centres. ShaRe
showed that patients with sarcomere gene variants
of unknown significance were diagnosed earlier and
had worse outcomes than HCM patients without gene
variants (gene variant-negative), while the risk of ad-
verse events was lower compared with HCM patients
with a proven pathogenic gene variant. This study
emphasises the need to further study the pathogenic-
ity of newly identified gene variants to improve risk
stratification and to enable predictive testing of family
members.
Finishing this ‘mission’ will require determination
and endurance as genetic heart disease in most in-
dividuals is a slowly developing disease. Yet, recent
studies highlighted that asymptomatic mutation car-
riers already show large changes in efficiency of car-
diac function in the absence of evident cardiac re-
modelling (fibrosis, hypertrophy) [9]. We therefore
need sensitive in vivo imaging modalities to trace the
early pathologic changes in the heart before overt car-
diac remodelling. Follow-up studies of both asymp-
tomatic and diseased gene variant carriers over many
years are warranted to define the exact pathomecha-
nisms underlying genetic heart disease, which in spite
of its frequency is relatively low compared with is-
chaemic heart disease. Genetic heart disease affects
young people and entire families and thereby places
a huge burden on society. Ultimately, we may be able
to initiate personalised medicine on the basis of the
identified gene variant.
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